JP2025509266A5 - - Google Patents
Info
- Publication number
- JP2025509266A5 JP2025509266A5 JP2024553327A JP2024553327A JP2025509266A5 JP 2025509266 A5 JP2025509266 A5 JP 2025509266A5 JP 2024553327 A JP2024553327 A JP 2024553327A JP 2024553327 A JP2024553327 A JP 2024553327A JP 2025509266 A5 JP2025509266 A5 JP 2025509266A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- cancer
- antibody
- targeted
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317472P | 2022-03-07 | 2022-03-07 | |
| US63/317,472 | 2022-03-07 | ||
| US202263329680P | 2022-04-11 | 2022-04-11 | |
| US63/329,680 | 2022-04-11 | ||
| PCT/US2023/063852 WO2023172906A1 (en) | 2022-03-07 | 2023-03-07 | Antibody drug conjugates comprising sting agonists, combinations and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509266A JP2025509266A (ja) | 2025-04-11 |
| JP2025509266A5 true JP2025509266A5 (https=) | 2026-03-13 |
Family
ID=85800735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553327A Pending JP2025509266A (ja) | 2022-03-07 | 2023-03-07 | Ｓｔｉｎｇアゴニストを含む抗体薬物コンジュゲート、組み合わせ、および使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230398229A1 (https=) |
| EP (1) | EP4489789A1 (https=) |
| JP (1) | JP2025509266A (https=) |
| KR (1) | KR20240150805A (https=) |
| CN (1) | CN119173277A (https=) |
| AU (1) | AU2023232820A1 (https=) |
| CA (1) | CA3245425A1 (https=) |
| IL (1) | IL315064A (https=) |
| MX (1) | MX2024010916A (https=) |
| TW (1) | TW202400241A (https=) |
| WO (1) | WO2023172906A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296901A (en) | 2020-04-02 | 2022-12-01 | Mersana Therapeutics Inc | Antibody-drug conjugates comprising sting agonists |
| WO2024192017A1 (en) * | 2023-03-13 | 2024-09-19 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists, combinations and methods of use |
| WO2026043823A2 (en) * | 2024-08-19 | 2026-02-26 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| JP6991857B2 (ja) | 2014-10-10 | 2022-01-13 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療 |
| US20180271996A1 (en) * | 2017-02-28 | 2018-09-27 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| EP4058024A1 (en) * | 2019-11-15 | 2022-09-21 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| IL296901A (en) * | 2020-04-02 | 2022-12-01 | Mersana Therapeutics Inc | Antibody-drug conjugates comprising sting agonists |
-
2023
- 2023-03-07 JP JP2024553327A patent/JP2025509266A/ja active Pending
- 2023-03-07 EP EP23714964.6A patent/EP4489789A1/en active Pending
- 2023-03-07 KR KR1020247031618A patent/KR20240150805A/ko active Pending
- 2023-03-07 MX MX2024010916A patent/MX2024010916A/es unknown
- 2023-03-07 CN CN202380039134.1A patent/CN119173277A/zh active Pending
- 2023-03-07 CA CA3245425A patent/CA3245425A1/en active Pending
- 2023-03-07 AU AU2023232820A patent/AU2023232820A1/en active Pending
- 2023-03-07 US US18/179,699 patent/US20230398229A1/en active Pending
- 2023-03-07 IL IL315064A patent/IL315064A/en unknown
- 2023-03-07 TW TW112108211A patent/TW202400241A/zh unknown
- 2023-03-07 WO PCT/US2023/063852 patent/WO2023172906A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025509266A5 (https=) | ||
| CN102812045B (zh) | 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法 | |
| HRP20240626T1 (hr) | Bispecifična antitijela protiv ceacam5 i cd3 | |
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2020516240A5 (https=) | ||
| JP2017514795A5 (https=) | ||
| JP2022548947A5 (https=) | ||
| JP2018505177A5 (https=) | ||
| JP2013510868A5 (https=) | ||
| JP2014509593A5 (https=) | ||
| JP2017514461A5 (https=) | ||
| JP2023507190A5 (https=) | ||
| JP2021531732A5 (https=) | ||
| JP2024546605A5 (https=) | ||
| US20250282875A1 (en) | Methods of treating colorectal cancer using an anti-ctla4 antibody | |
| JP2023519807A5 (https=) | ||
| JP2023510199A5 (https=) | ||
| JP2024518536A5 (https=) | ||
| CA3099406A1 (en) | Antibodies against lif and dosage forms thereof | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| CN114729054A (zh) | 使用免疫检查点抑制剂抗体治疗癌症的方法和组合 | |
| JP2023103352A5 (https=) | ||
| JPWO2021251459A5 (https=) | ||
| JP2015518824A5 (https=) | ||
| JP2022530272A5 (https=) |